Floatz logo

[18F]ACI-19626

TDP-43 Proteinopathies

AC Immune SAEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the TDP-43 Proteinopathies cohort.

Asset / SponsorPhaseRating
Rotigotine
I.R.C.C.S. Fondazione Santa Lucia
Phase 2B
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 2B
TAMOXIFEN
Taipei Medical University Shuang Ho Hospital
Phase 1/2CCC

Same molecule, other indications

[18F]ACI-19626 is also rated in:

frontotemporal dementiaDormant
C
Indicative ·
39 / 100
View asset →
Alzheimer diseaseDormant
C
Indicative ·
39 / 100
View asset →
amyotrophic lateral sclerosisDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →